Renaissance Technologies LLC raised its position in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 23.7% during the first quarter, according to its most recent disclosure with the SEC. The firm owned 574,051 shares of the biopharmaceutical company’s stock after buying an additional 110,100 shares during the period. Renaissance Technologies LLC’s holdings in Dynavax Technologies Corporation were worth $3,416,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the stock. Russell Investments Group Ltd. acquired a new stake in Dynavax Technologies Corporation during the fourth quarter worth about $317,000. Kornitzer Capital Management Inc. KS boosted its stake in Dynavax Technologies Corporation by 90.3% in the first quarter. Kornitzer Capital Management Inc. KS now owns 1,098,510 shares of the biopharmaceutical company’s stock worth $6,536,000 after buying an additional 521,310 shares during the last quarter. Teachers Advisors LLC boosted its stake in Dynavax Technologies Corporation by 9.1% in the fourth quarter. Teachers Advisors LLC now owns 67,640 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 5,618 shares during the last quarter. Quantitative Investment Management LLC acquired a new stake in Dynavax Technologies Corporation during the first quarter worth about $1,404,000. Finally, Nationwide Fund Advisors boosted its stake in Dynavax Technologies Corporation by 11.2% in the first quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 2,786 shares during the last quarter. 56.05% of the stock is owned by institutional investors.

Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) traded up 3.47% during trading on Friday, hitting $16.40. The stock had a trading volume of 727,881 shares. Dynavax Technologies Corporation has a 52 week low of $3.20 and a 52 week high of $19.60. The company’s market capitalization is $897.85 million. The company’s 50 day moving average price is $11.52 and its 200 day moving average price is $7.04.

Dynavax Technologies Corporation (NASDAQ:DVAX) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The business had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.15 million. During the same quarter in the prior year, the business earned ($0.75) earnings per share. Analysts predict that Dynavax Technologies Corporation will post ($1.58) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Dynavax Technologies Corporation (DVAX) Position Raised by Renaissance Technologies LLC” was first posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/dynavax-technologies-corporation-dvax-position-raised-by-renaissance-technologies-llc/1475241.html.

A number of analysts have recently issued reports on DVAX shares. Cowen and Company reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Royal Bank Of Canada set a $7.00 price objective on Dynavax Technologies Corporation and gave the company a “hold” rating in a research report on Wednesday, July 26th. ValuEngine cut Dynavax Technologies Corporation from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Finally, J P Morgan Chase & Co raised Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $6.00 to $27.00 in a research report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $23.34.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.